Adrian Hernandez, MD
Cardiovascular Disease · Durham, NCNPI 1902980063
Payments from drug & device makers
Across 406 payments — averaging $32,434 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$10.2M
- Pfizer$1.6M
- Janssen Scientific Affairs, LLC$609K
- AstraZeneca$235K
- GSK$120K
- Genentech, Inc.$106K
- plus $327K from 18 others
Across 14 payments — averaging $403.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$3K
- GSK$2K
- Novartis Pharma AG$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 101 | $10,211,734 |
| Pfizer | 20 | $1,558,522 |
| Janssen Scientific Affairs, LLC | 7 | $609,020 |
| AstraZeneca | 23 | $235,200 |
| GSK | 9 | $120,415 |
| Genentech, Inc. | 1 | $106,066 |
| Boston Scientific | 82 | $80,584 |
| Novo Nordisk AS | 10 | $44,242 |
| E.r. Squibb & Sons, L.L.C. | 30 | $37,524 |
| Intercept Pharmaceuticals, Inc. | 15 | $37,400 |
| Novartis | 28 | $30,857 |
| Boehringer Ingelheim International GmbH | 11 | $27,063 |
| Astrazeneca AB | 11 | $16,220 |
| Sanofi-aventis U.S. LLC | 6 | $13,985 |
| Novo Nordisk | 11 | $10,437 |
| Eli Lilly | 3 | $9,000 |
| Amgen | 12 | $5,163 |
| Vifor Pharma, Inc. | 7 | $4,430 |
| Bayer | 7 | $4,323 |
| Boehringer Ingelheim RCV GmbH & Co KG | 1 | $3,850 |
| CSL Behring | 2 | $1,661 |
| Astrazeneca UK Limited | 7 | $379 |
| Alnylam Pharmaceuticals Inc. | 1 | $55 |
| Johnson & Johnson | 1 | $17 |
How this compares
$13,168,146 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Durham
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
- Nishant ShahDurham$3.5M
- Andrew AmbrosyDurham$3.2M
- Michel KhouriDurham$2.4M
- R WilliamsDurham$2.1M
- Andrew WangDurham$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.